Anebulo Pharmaceuticals (NASDAQ:ANEB) Receives Speculative Buy Rating from Benchmark

Benchmark reiterated their speculative buy rating on shares of Anebulo Pharmaceuticals (NASDAQ:ANEB) in a report released on Tuesday,Benzinga reports. They currently have a $8.00 price target on the stock.

Anebulo Pharmaceuticals Price Performance

Shares of NASDAQ:ANEB opened at $1.46 on Tuesday. The company has a market capitalization of $37.86 million, a price-to-earnings ratio of -4.87 and a beta of -1.00. The business’s 50-day moving average is $1.86 and its 200-day moving average is $2.08. Anebulo Pharmaceuticals has a 1 year low of $1.25 and a 1 year high of $3.30.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last announced its quarterly earnings data on Wednesday, September 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.08. Analysts anticipate that Anebulo Pharmaceuticals will post -0.52 EPS for the current year.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.